TABLE 2.

Outcomes of tigecycline treatment for CDI from case series

Outcome	Nonsevere infection	Severe infection	Fulminant infection
Avg length of tigecycline therapy	7.4 days (range 0.5–13.6)	7.75 days (range 2.5–20.3)	7.7 days (range 0.5–27.5)
Tigecycline used as initial, salvage, or nondirected therapya	Salvage	Salvage	=
In-hospital mortality	2 of 7 (29%)	2 of 12 (17%)	5 of 9 (56%)
90-day mortality	2 of 7 (29%)	2 of 12 (17%)	6 of 9 (67%)
Recurrences at 30 days	0	2	1
Recurrences at 90 days	0	5	1
Total recurrences	5 (in 2/5 [40%] surviving patients)	5 (in 5/10 [50%] surviving patients)	1 (in 1/2 [50%] surviving patients who reached follow-up)

^aInitial therapy is defined as tigecycline use within 7 days from day 0: the earliest of the date of positive stool test, the start of directed antimicrobial therapy, or the start of tigecycline therapy. Salvage therapy is defined as tigecycline use after 7 days from day 0. An equals sign indicates that tigecycline was used as initial, salvage, or nondirected therapy in an equal number of cases.